Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 26 points (0.2%) at 15,572 as of Tuesday, July 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,636 issues advancing vs. 1,285 declining with 117 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Waters Corporation ( WAT), down 5.9%, Boston Scientific ( BSX), down 2.4%, Alexion Pharmaceuticals ( ALXN), down 2.0%, Vertex Pharmaceuticals ( VRTX), down 1.0% and Sanofi ( SNY), down 0.6%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $1.92 (1.2%) to $165.17 on average volume. Thus far, 167,761 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 305,100 shares. The stock has ranged in price between $163.67-$165.17 after having opened the day at $164.29 as compared to the previous trading day's close of $163.25. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $89.9 billion and is part of the drugs industry. Shares are up 0.1% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.